Clinical Trial Update: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis [EARLY_Phase 1]

View source ↗

Summary

An EARLY Phase 1 trial evaluating RP1 in primary melanoma to reduce the risk of sentinel lymph node metastasis; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RP1

Snippet

Sponsor: Yana Najjar | Conditions: Melanoma | EARLY_Phase 1 | Status: RECRUITING